Clover Health Investments Q1 Earnings Call Highlights

Key Points

• Clover reported Q1 2026 results showing 51% membership growth year‑over‑year to about 156,000 members, GAAP net income of $27 million, revenue of $749 million (+62% y/y), adjusted EBITDA of $40 million (+56% y/y), and ended the quarter with $418 million in cash and no debt.
• The company runs a full‑risk wide‑network PPO that retains economics and treats higher first‑year medical costs and acquisition spend as deliberate upfront investments, expecting cohort profitability to improve as retention and cohorts mature.
• Clover is scaling its care and data platform—over one‑third of members used Clover Assistant in Q1, home care enrollments were a record, and early access to CMS aligned networks plus AI investments are cited as a structural advantage for managing medical costs and operations.

Clover Health Investments NASDAQ: CLOV reported first-quarter 2026 results that management said demonstrated the ability to combine rapid Medicare Advantage growth with GAAP profitability as the company continues scaling its technology-driven care model.

Membership growth and GAAP profitability

Chief Executive Officer Andrew Toy said the company entered 2026 with “market-leading growth, GAAP net income profitability, and full risk” scaling together in Medicare Advantage. Clover grew membership 51% year over year in the quarter and generated GAAP net income of $27 million, according to Toy.

Interim Chief Financial Officer Clay Thornton provided additional detail, stating that Medicare Advantage membership increased by more than 52,000 lives year over year to approximately 156,000 members. Total revenue was $749 million, up 62% year over year. Consolidated gross profit was $160 million, up 47% year over year, reflecting what Thornton described as strong revenue growth alongside stable medical cost performance.

Thornton said adjusted EBITDA was $40 million, increasing 56% year over year. He added that the company ended the quarter with $418 million in total cash and investments and “no debt outstanding.” Cash flow from operations was $108 million, which he attributed to underlying business performance and “timing-related working capital favorability as a result of our strong membership growth.”

Strategy: Full-risk PPO model and cohort maturation

Toy emphasized that Clover’s model differs from many Medicare Advantage peers because it operates a wide-network PPO structure and “retain[s] full economics,” generally without delegating risk to providers. He described new-member acquisition and higher first-year medical costs as intentional upfront investments, with the expectation that profitability improves as cohorts mature under Clover’s platform.

“As new members join, we view their cost of acquisition and first-year medical costs as deliberate upfront investments,” Toy said, adding that the initial year includes assessments, enrollment of higher-need members into home care, and efforts to increase Clover Assistant-powered interactions.

Thornton also highlighted retention as a key input into the company’s cohort economics. He said growth in the quarter was driven “primarily by a strong AEP,” including “best-in-class retention,” which he called one of the most important leading indicators of long-term cohort profitability. During the open enrollment period (OEP), he said Clover “intentionally moderate[d] the pace of new member growth,” prioritizing operational readiness and clinical capacity following what he characterized as a very strong AEP.

Toy pointed to Clover’s New Jersey footprint as an example of scale driving deeper integration. He said that, excluding special needs and employer retiree plans, Clover is now “the largest PPO in New Jersey.”

Care model execution: Clover Assistant, home care, and interoperability

In the quarter, Toy said Clover Assistant and Clover Care Services supported engagement across a wide-network physician base and helped deliver home-based care for higher acuity members. He stated that over one-third of Clover members received Clover Assistant-powered care in the first quarter, in line with expectations and tracking toward full-year targets. Toy also said the home care division enrolled “a record number of patients for this point in the year.”

Toy further discussed Clover’s data strategy, noting the company recently became “1 of the first payers active on the new CMS aligned networks,” which he said allows access to more data earlier in the member life cycle to power “more effective AI-driven insights.” He described interoperability as a “core capability,” rather than primarily a compliance exercise.

Thornton said the company is investing in its AI and data platform, which he called a “structural advantage” in managing medical costs and operating expenses. He also said Clover is investing in Counterpart Health in product development and go-to-market capabilities, describing early traction with “growing provider adoption in markets where we do not currently operate plans.”

Medical cost trends: Inpatient improvement, outpatient elevation, and dental remediation

Thornton said inpatient utilization was “meaningfully lower” year over year in the first quarter, with lower flu and COVID-related utilization contributing approximately 25 to 30 basis points of favorability to overall margin versus 2025. He added that the company is seeing early evidence that increased clinical engagement is helping manage utilization, especially among higher acuity members.

He said enrollment in Clover Care Services programs increased about 90% year over year, reflecting the company’s ability to engage members earlier. At the same time, Thornton said outpatient utilization and costs “continue to be elevated,” consistent with expectations, citing increased service intensity and provider billing patterns that began accelerating in the back half of 2025. He said Clover is addressing this by leveraging data and AI-driven insights for medical expense management.

On supplemental benefits, Thornton said the company made “substantial progress” in dental cost management after remediation and recovery actions implemented in 2025. While utilization remained stable year over year, he said Clover is seeing “meaningful cost reductions” tied to structural changes in how out-of-network dental claims are handled.

Regarding Part D, Thornton said performance was developing in line with expectations as the company moves into the second year of Inflation Reduction Act implementation, while noting the company is monitoring risk adjustment normalization and trend acceleration among non-low-income members.

Thornton reported an insurance benefit expense ratio (BER) of 86.5% for the quarter, which he said reflected strong performance as well as ongoing investment in quality improvement.

Expenses, guidance posture, and 2027 policy backdrop

Adjusted SG&A was $119 million, or 16% of revenue, improving about 200 basis points year over year, Thornton said. He attributed the improvement to scale efficiencies, vendor optimization, more disciplined variable growth spending, and early benefits from automation and AI-driven workflows.

During the Q&A, Thornton noted some “one-time non-recurring expenses” in first-quarter SG&A, including a non-cash claims adjustment expense tied to growth in membership and reserves. He said the item “won’t be recurring for the remainder of the year.”

On outlook, Thornton said Clover expects to meet or exceed its full-year 2026 outlook across all metrics, but plans to revisit guidance after second-quarter results to establish a more complete baseline for trends. He reiterated that, while encouraged, management is maintaining discipline given it is still early in the year.

Asked about new versus existing cohorts and risk adjustment factor (RAF) scores, Thornton said the company has good visibility into leading indicators through the first quarter and that trends were tracking in line with expectations. He also disclosed “modest unfavorability” from prior year development in the quarter, including normal reserve true-ups and “slight unfavorability on the revenue side.”

Toy also addressed the 2027 policy environment, saying it was too early to discuss bids in detail but that Clover feels well positioned across both 3.5- and 4-Star ratings. He said CMS did not finalize proposed risk model changes, creating more stability than many expected. Toy added that Clover expects minimal year-over-year impact from changes involving unlinked chart reviews and said the company was pleased CMS addressed plan-switching dynamics with a “switcher exception.”

In closing remarks, Toy said the company is seeing “strong growth and profitability come through at the same time,” with cohorts developing as expected and the care model scaling as designed. He reiterated Clover’s expectation to deliver full-year GAAP net income profitability in 2026 while continuing to invest in care model capabilities, technology, and longer-term initiatives.

About Clover Health Investments NASDAQ: CLOV

Clover Health Investments is a technology-driven healthcare company specializing in Medicare Advantage plans for senior populations. The company combines insurance coverage with a proprietary software platform to improve care coordination, outcomes tracking and cost management. By leveraging data analytics, Clover Health aims to deliver personalized care pathways and preventive interventions for its members.

At the core of Clover's offering is its Clover Assistant platform, which aggregates clinical and claims data from multiple sources to create real-time insights for physicians and care teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.